NewsDesk @bactiman63 A new antimalarial drug is being introduced at a dose that is too low to be effective for all patients who need it, according to a report published in eLife. The study suggests that...

By NewsDesk  @bactiman63 Vaccine company, Valneva, announced Monday positive antibody persistence data twelve months after vaccination with a single dose of its chikungunya vaccine candidate, VLA1553. Following...

By NewsDesk  @bactiman63 Fungi in the soil cause a significant number of serious lung infections in 48 out of 50 states and the District of Columbia, including many areas long thought to be free of deadly...

NewsDesk @bactiman63 A new, single-dose, oral treatment for sleeping sickness is as effective as current treatments and could be a key factor in eliminating disease transmission by 2030, suggests a new...

Tick-borne pathogens, known for causing illnesses such as Lyme disease, are on the rise in Central Canada – presenting new risks in areas where they were never previously detected. The findings from...

By NewsDesk  @bactiman63 A new study by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, demonstrated that shingles, also known as...

There is no FDA-approved human vaccine for nontyphoidal salmonella, which kills hundreds of thousands of people and sickens an estimated 93.8 million globally each year. Nontyphoidal salmonella is the...

Monkeypox has infected more than 77,000 people in more than 100 countries worldwide, and — similar to COVID-19 — mutations have enabled the virus to grow stronger and smarter, evading antiviral drugs...

By NewsDesk  @bactiman63 Clinical-stage biopharmaceutical company, Atea Pharmaceuticals, Inc., today presented a poster highlighting favorable AT-752 Phase 1 clinical data for the treatment of dengue...

A large-scale comparison of direct oral anticoagulants (blood thinners), commonly prescribed for irregular heartbeats, has identified the drug with the lowest risk of bleeding, in a new study led by UCL...